Please log in to view this page
Username
Password
A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...
This is a Phase I, multi-site, open-label, non-comparative study of the PK, safety, tolerability, and acceptability of a...
REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....
This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...
The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...
